FGFR1::TACC1融合的低级别神经上皮肿瘤七例临床病理分析
回顾性分析7例经确认携带FGFR1::TACC1融合的低级别神经上皮肿瘤,患者均为男性,中位年龄14岁,肿瘤多位于小脑。组织学均见少突胶质样细胞伴神经毡岛和水肿间质,DNA甲基化分型归入多个参考类别,全切除后随访36–60个月未见复发。
要点
- FGFR1::TACC1融合肿瘤多见于男性青少年,好发于小脑。
- 组织学特征为少突胶质样细胞、神经毡岛和水肿间质。
- 全切除后随访36–60个月未见肿瘤复发。
核心结论
- FGFR1::TACC1融合的低级别神经上皮肿瘤为异质性实体,同一融合可对应不同组织形态和DNA甲基化谱。
研究设计与样本
- 回顾性分析7例经确认FGFR1::TACC1融合的肿瘤,复习临床、病理、免疫组化、NGS和DNA甲基化聚类资料。
主要发现
- 所有患者均为男性,中位年龄14岁,肿瘤主要位于小脑。
- MRI主要表现为囊实性病变,T1低信号,FLAIR边界较清。
- 组织学均见少突胶质样细胞、神经毡岛和水肿间质,分支毛细血管6/7、钙化4/7、Rosenthal纤维3/7。
- 免疫组化GFAP和Olig2全例阳性,Syn阳性4例,局灶NeuN阳性2例,局灶CD34阳性1例,Ki-67均低于5%。
- DNA甲基化分型归入LGG、DNT、PA PF和ANA PA等多个参考类别,未检出显著染色体臂级拷贝数改变。
关键数值与推荐
- NGS确认每例均存在FGFR1::TACC1融合。
- Ki-67低于5%。
- 随访36–60个月未见肿瘤复发。
临床怎么用
- 对男性青少年小脑囊实性低级别肿瘤,应结合组织学、免疫组化和NGS检测FGFR1::TACC1融合。
- 全切除后可根据多学科讨论决定是否辅助放疗,本组仅1例接受辅助放疗。
局限性
- 回顾性分析,样本量仅7例。
- 随访时间36–60个月,不足以评估长期复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To characterize the clinicopathologic, radiologic, immunophenotypic, and molecular features of low-grade neuroepithelial tumor harboring FGFR1::TACC1 fusion. METHODS: Seven cases with confirmed FGFR1::TACC1 fusion were retrospectively analyzed. Clinical information, histopathological features, immunohistochemical profiles, next-generation sequencing (NGS) results and DNA methylation–based clustering analyses were reviewed. RESULTS: All patients were male, with a median age of 14 years. Tumors were predominantly located in the cerebellum. Magnetic resonance imaging revealed mainly cystic–solid lesions with hypointensity on T1-weighted imaging and relatively well-defined margins on FLAIR sequences. Histologically, all tumors exhibited oligodendroglia-like cells with round nuclei and perinuclear halos, accompanied by neurofibrillary islands and edematous stroma. Branching capillaries (6/7), calcifications (4/7), and Rosenthal fibers (3/7) were variably observed. One case demonstrated morphologic and immunophenotypic features overlapping with extraventricular neurocytoma. Immunohistochemistry demonstrated GFAP and Olig2 expression in all cases; Syn positivity was identified in four cases and focal NeuN positivity in two cases. Focal CD34 expression was found in one. The Ki-67 was below 5% in all tumors. NGS confirmed FGFR1::TACC1 fusion in every case. DNA methylation profiling assigned tumors to multiple reference classes, including low-grade glioma (LGG), dysembryoplastic neuroepithelial tumor (DNT), pilocytic astrocytoma, posterior fossa (PA PF) and anaplastic pilocytic astrocytoma (ANA PA). No significant chromosomal arm-level copy number alterations were detected. All patients underwent gross resection, with one receiving adjuvant radiotherapy. No tumor recurrence was observed during follow-up (36–60 months). CONCLUSION: Low-grade neuroepithelial tumors with FGFR1::TACC1 fusion represent a heterogeneous entity where a single recurrent gene fusion may be associated with diverse histomorphologic features and variable DNA methylation profiles.
引用
- Yang M, Zhou D, Fan J, et al. Low-grade neuroepithelial tumor with FGFR1::TACC1 fusion: a clinicopathologic analysis of seven cases. J Neurooncol. 2026. PMID: 41995891. doi:10.1007/s11060-026-05577-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。